SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a non-exclusive license agreement with Pfizer for its Matrix-M adjuvant, providing significant validation for the technology. This deal, building on previous collaborations, is driving community excitement and fueling discussions about the adjuvant's potential applications and the company's future partnerships amidst notable short interest.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is driving significant conversation as escalating US-EU trade tensions, particularly over Greenland and proposed tariffs, spark widespread market uncertainty and a risk-off shift. The community is sharply divided, with intense debate over whether current volatility signals a deeper correction or presents a key buying opportunity amidst ongoing institutional interest and broader macroeconomic shifts.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is currently experiencing a significant surge, fueled by an intense Arctic air invasion across the United States that is driving up natural gas demand and futures prices. The strong upward momentum has triggered a notable short squeeze, with the community actively discussing substantial profits and anticipating continued upside as extreme cold weather is projected to persist. This volatility is characteristic of the 2x leveraged ETF, attracting both profit-takers and those eyeing further gains.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a major talking point among investors, primarily driven by its upcoming earnings report and the proposed all-cash acquisition of Warner Bros. Discovery assets, which has sparked a debate over potential growth versus debt concerns. The community is closely watching for strong ad-tier performance and subscriber metrics, particularly after a previous tax-related earnings miss, with sentiment split on whether recent oversold conditions signal a significant rebound or continued volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is generating significant buzz following positive regulatory advancements for its ANKTIVA therapy, with the FDA outlining a path to resubmission for papillary bladder cancer that requires no new clinical trials. This news, combined with recent international approvals, is fueling strong community sentiment around the potential for a "cancer cure" and intense discussions anticipating a substantial short squeeze.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as market participants react to heightened geopolitical tensions, specifically former President Trump's recent tariff threats against NATO allies over Greenland and an anticipated Supreme Court ruling on presidential tariff authority. This has sparked a fierce debate among investors, with some advocating to "buy the dip" and anticipating a rapid "Taco Trade" rebound, while others warn of a significant market correction. Adding to the volatility are concerns surrounding Japan's bond market instability, creating a complex and uncertain trading environment.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin ($APP) is experiencing significant volatility and a notable price decline following a new short report alleging the company's involvement in money laundering. This report has sparked intense debate among investors, with many attributing the drop to market manipulation and viewing it as a buying opportunity, while others express concern over the serious accusations despite recent bullish analyst upgrades.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to overwhelmingly positive data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis, with community discussions highlighting its strong efficacy in treatment-resistant patients. Investors are actively debating the potential for this novel oral ITK inhibitor to disrupt the significant atopic dermatitis market, fueling speculation of future partnerships or an acquisition and validating its broader immune-modulating platform.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is experiencing significant volatility amid escalating geopolitical tensions, notably the US asserting control over Venezuela's oil and ongoing debates surrounding US tariffs, fueling a "flight to quality" narrative for some. The community is actively discussing whether these events, alongside large institutional bond purchases, will continue to boost Treasuries as a safe haven or intensify concerns over US debt and the Federal Reserve's independence.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending as natural gas prices sharply reverse, primarily driven by dramatically warmer weather forecasts that are erasing previous cold-snap gains. The community is actively discussing the extreme volatility and "widow maker" nature of natural gas ETFs, with many attempting to capitalize on KOLD's rapid ascent amidst widespread price uncertainty. This significant shift in winter weather expectations is compelling traders to adjust positions, leading to rapid price movements in inverse natural gas products.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Turn Therapeutics' (TTRX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated a "buy" rating and issued a $8.00 price target on shares of Turn Therapeutics in a report on Tuesday...

Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference

Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic and infectious diseases, today announced...

Turn Therapeutics (NASDAQ:TTRX) Upgraded to "Strong-Buy" at D Boral Capital

D Boral Capital upgraded shares of Turn Therapeutics to a "strong-buy" rating in a research report on Monday...

Turn Therapeutics (NASDAQ:TTRX) Coverage Initiated at D. Boral Capital

D. Boral Capital assumed coverage on Turn Therapeutics in a research report on Monday. They set a "buy" rating and a $8.00 price target on the stock...

Turn Therapeutics (NASDAQ:TTRX) Director Purchases $33,945.92 in Stock

Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report) Director Arthur Golden bought 9,868 shares of Turn Therapeutics stock in a transaction that occurred on Monday, November 24th. The stock was...

Insider Buying: Turn Therapeutics (NASDAQ:TTRX) Director Buys 20,532 Shares of Stock

Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report) Director Arthur Golden acquired 20,532 shares of Turn Therapeutics stock in a transaction dated Friday, November 21st. The shares were bought at...

Turn Therapeutics (NASDAQ:TTRX) Releases Quarterly Earnings Results

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.07) EPS for the quarter...

Shares of Turn Therapeutics&nbsp;surged over 370% in early premarket trade on Thursday,&nbsp;extending&nbsp;gains&nbsp;from the after-hours session on the Nasdaq Capital Market after the California-based biotech made its public listing on Wednesday.&nbsp;The U.S. Securities and Exchange Commission had declared Turn’s registration statement effective on Sept. 30, clearing the way for the IPO.<a href="https://stocktwits.com/symbol/TTRX">Turn Therapeutics’ stock</a> surged 134% to $9.40 in extended trading on Wednesday, placing it among the top after-hours gainers on the day.Founder and CEO Bradley Burnham said during the Nasdaq closing bell ceremony that the company was “built on a shoestring, with an absolute disdain for waste,” highlighting its lean approach to research and operations.&nbsp;Turn Therapeutics develops and commercializes next-generation products for dermatology, wound care, and infectious diseases, with three FDA-cleared medical devices and late-stage clinical programs in eczema and onychomycosis.&nbsp;Its proprietary formula targets inflammatory cytokines such as IL-36a, IL-36y, IL-4, and IL-31, and has been confirmed as non-cytotoxic and non-sensitizing.&nbsp;The company also develops formulations that are 99.9% effective against Methicillin-Resistant Staphylococcus aureus, a type of bacteria that’s resistant to many commonly used antibiotics, and qualify for the FDA’s Qualified Infectious Disease Product (QIDP) program.Turn has also developed its Permafusion platform, which allows pharmaceutical ingredients to penetrate deeper skin and tissue layers without emulsifiers, improving bioavailability and minimizing side effects.&nbsp;Beyond dermatology and wound care, Turn is developing thermostable vaccine delivery technology to expand access to essential medicines in underserved global markets.The company’s financial advisor for the listing was Clear Street LLC, with legal counsel provided by Davis Polk &amp; Wardwell LLP.&nbsp;On Stocktwits, retail sentiment was ‘neutral’ amid ‘extremely low’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Turn Therapeutics’ stock (TTRX) surged 134% to $9.40 in extended trading on Wednesday, placing it among the top after-hours gainers on the day. (Representative Image: Getty Images)

Why Is Turn Therapeutics Stock Soaring Over 370% Premarket Today?

The stock’s debut on Wednesday followed the SEC’s approval of its registration statement on Sept. 30, clearing the way for its public listing as it advances late-stage clinical programs in eczema and onychomycosis.

Equity

Turn Therapeutics, Inc. is a pharmaceutical and medical device development company. Its primary development programs focus on dermatological diseases. The company was founded on January 6, 2015 and is headquartered in Westlake Village, CA.

TTRX
Turn Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TTRX News

TTRXTurn Therapeutics Inc